menu
    • menu

    Company profile for Uniqure

    NEW Drugs in Dev: 11
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. We are advancing a focused pipeline of innovative gene therapies. We are currently condu...
    uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. We are advancing a focused pipeline of innovative gene therapies. We are currently conducting a pivotal phase 3 trial in our lead indication, hemophilia B, and have initiated a phase 1/2 trial in Huntington’s disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    UniqureNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Paasheuvelweg 25a 1105BP Amsterdam
    Telephone
    Telephone
    +1 339 970 7000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.uniqure.com/index.php
    Linkedin
    Linkedin
    https://www.linkedin.com/company/uniqure
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/uniQure_NV

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    ChemTides

    Not Confirmed

    envelop Contact Supplier

    ChemTides

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA official calls UniQure's Huntington's disease treatment a fai
    FDA official calls UniQure's Huntington's disease treatment a fai

    06 Mar 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/sr-fda-official-calls-uniqures-huntingtons-disease-treatment-failure-2026-03-05/

    REUTERS
    06 Mar 2026
    Share Share
    Senior FDA Official Fires Back At Uniqure Amid Controversy
    Senior FDA Official Fires Back At Uniqure Amid Controversy

    05 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/senior-fda-official-refutes-uniqure-claims-amid-controversy-over-huntingtons-gene-therapy

    FIERCE BIOTECH
    05 Mar 2026
    Share Share
    Uniqure, FDA Back-And-Forth Intensifies
    Uniqure, FDA Back-And-Forth Intensifies

    05 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/pressure-builds-back-and-forth-between-uniqure-and-fda-intensifies

    FIERCE BIOTECH
    05 Mar 2026
    Share Share
    uniQure Provides Update on AMT-130 for Huntington’s Disease
    uniQure Provides Update on AMT-130 for Huntington’s Disease

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247236/0/en/uniQure-Provides-Regulatory-Update-on-AMT-130-for-Huntington-s-Disease.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Uniqure Reveals 2025 Financials And Company Updates
    Uniqure Reveals 2025 Financials And Company Updates

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247245/0/en/uniQure-Announces-2025-Financial-Results-and-Provides-Recent-Company-Updates.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    UniQure To Report 2025 Financial Results
    UniQure To Report 2025 Financial Results

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242490/0/en/uniQure-to-Announce-2025-Financial-Results.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search